116 related articles for article (PubMed ID: 10944598)
1. A phase I study of a new polyamine biosynthesis inhibitor, SAM486A, in cancer patients with solid tumours.
Paridaens R; Uges DR; Barbet N; Choi L; Seeghers M; van der Graaf WT; Groen HJ; Dumez H; Buuren IV; Muskiet F; Capdeville R; Oosterom AT; de Vries EG
Br J Cancer; 2000 Sep; 83(5):594-601. PubMed ID: 10944598
[TBL] [Abstract][Full Text] [Related]
2. A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with Advanced solid malignancies.
Siu LL; Rowinsky EK; Hammond LA; Weiss GR; Hidalgo M; Clark GM; Moczygemba J; Choi L; Linnartz R; Barbet NC; Sklenar IT; Capdeville R; Gan G; Porter CW; Von Hoff DD; Eckhardt SG
Clin Cancer Res; 2002 Jul; 8(7):2157-66. PubMed ID: 12114416
[TBL] [Abstract][Full Text] [Related]
3. Phase I and pharmacological study of weekly administration of the polyamine synthesis inhibitor SAM 486A (CGP 48 664) in patients with solid tumors. European Organization for Research and Treatment of Cancer Early Clinical Studies Group.
Eskens FA; Greim GA; van Zuylen C; Wolff I; Denis LJ; Planting AS; Muskiet FA; Wanders J; Barbet NC; Choi L; Capdeville R; Verweij J; Hanauske AR; Bruntsch U
Clin Cancer Res; 2000 May; 6(5):1736-43. PubMed ID: 10815892
[TBL] [Abstract][Full Text] [Related]
4. CGP 48664, a new S-adenosylmethionine decarboxylase inhibitor with broad spectrum antiproliferative and antitumor activity.
Regenass U; Mett H; Stanek J; Mueller M; Kramer D; Porter CW
Cancer Res; 1994 Jun; 54(12):3210-7. PubMed ID: 8205541
[TBL] [Abstract][Full Text] [Related]
5. Multi-centre Phase II trial of the polyamine synthesis inhibitor SAM486A (CGP48664) in patients with metastatic melanoma.
Millward MJ; Joshua A; Kefford R; Aamdal S; Thomson D; Hersey P; Toner G; Lynch K
Invest New Drugs; 2005 Jun; 23(3):253-6. PubMed ID: 15868382
[TBL] [Abstract][Full Text] [Related]
6. Biological activity of the S-adenosylmethionine decarboxylase inhibitor SAM486A in human breast cancer cells in vitro and in vivo.
Hu X; Washington S; Verderame MF; Demers LM; Mauger D; Manni A
Int J Oncol; 2004 Dec; 25(6):1831-8. PubMed ID: 15547724
[TBL] [Abstract][Full Text] [Related]
7. A phase I, first in man study of OSI-7836 in patients with advanced refractory solid tumors: IND.147, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group.
Goss G; Siu LL; Gauthier I; Chen EX; Oza AM; Goel R; Maroun J; Powers J; Walsh W; Maclean M; Drolet DW; Rusk J; Seymour LK;
Cancer Chemother Pharmacol; 2006 Nov; 58(5):703-10. PubMed ID: 16528532
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics/toxicodynamics (PK/TD) relationship of SAM486A in phase I studies in patients with advanced cancers.
Zhou H; Choi L; Lau H; Bruntsch U; Vries EE; Eckhardt G; Oosterom AT; Verweij J; Schran H; Barbet N; Linnartz R; Capdeville R
J Clin Pharmacol; 2000 Mar; 40(3):275-83. PubMed ID: 10709156
[TBL] [Abstract][Full Text] [Related]
9. New S-adenosylmethionine decarboxylase inhibitors with potent antitumor activity.
Regenass U; Caravatti G; Mett H; Stanek J; Schneider P; Müller M; Matter A; Vertino P; Porter CW
Cancer Res; 1992 Sep; 52(17):4712-8. PubMed ID: 1511437
[TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy, tolerability, and safety of SAM486A, a novel polyamine biosynthesis inhibitor, in patients with relapsed or refractory non-Hodgkin's lymphoma: results from a phase II multicenter study.
Pless M; Belhadj K; Menssen HD; Kern W; Coiffier B; Wolf J; Herrmann R; Thiel E; Bootle D; Sklenar I; Müller C; Choi L; Porter C; Capdeville R
Clin Cancer Res; 2004 Feb; 10(4):1299-305. PubMed ID: 14977828
[TBL] [Abstract][Full Text] [Related]
11. A phase I and pharmacokinetic study of 1843U89, a noncompetitive inhibitor of thymidylate synthase, in patients with advanced solid malignancies.
Schwartz G; Johnson TR; Goetz A; Burris H; Smetzer L; Lampkin T; Sailstad J; Hohneker JA; Von Hoff DD; Rowinsky EK
Clin Cancer Res; 2001 Jul; 7(7):1901-11. PubMed ID: 11448903
[TBL] [Abstract][Full Text] [Related]
12. A phase I and pharmacologic evaluation of the DNA intercalator CI-958 in patients with advanced solid tumors.
Dees EC; Whitfield LR; Grove WR; Rummel S; Grochow LB; Donehower RC
Clin Cancer Res; 2000 Oct; 6(10):3885-94. PubMed ID: 11051234
[TBL] [Abstract][Full Text] [Related]
13. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
[TBL] [Abstract][Full Text] [Related]
14. Phase 1 study of weekly polyethylene glycol-camptothecin in patients with advanced solid tumors and lymphomas.
Posey JA; Saif MW; Carlisle R; Goetz A; Rizzo J; Stevenson S; Rudoltz MS; Kwiatek J; Simmons P; Rowinsky EK; Takimoto CH; Tolcher AW
Clin Cancer Res; 2005 Nov; 11(21):7866-71. PubMed ID: 16278410
[TBL] [Abstract][Full Text] [Related]
15. Phase I and pharmacokinetic study of the novel oral cell-cycle inhibitor Ro 31-7453 in patients with advanced solid tumors.
Dupont J; Bienvenu B; Aghajanian C; Pezzulli S; Sabbatini P; Vongphrachanh P; Chang C; Perkell C; Ng K; Passe S; Breimer L; Zhi J; DeMario M; Spriggs D; Soignet SL
J Clin Oncol; 2004 Aug; 22(16):3366-74. PubMed ID: 15310782
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor in patients with refractory solid tumors.
Beutel G; Glen H; Schöffski P; Chick J; Gill S; Cassidy J; Twelves C
Clin Cancer Res; 2005 Aug; 11(15):5487-95. PubMed ID: 16061865
[TBL] [Abstract][Full Text] [Related]
17. Lysosomal sequestration of polyamine analogues in Chinese hamster ovary cells resistant to the S-adenosylmethionine decarboxylase inhibitor, CGP-48664.
Kramer DL; Black JD; Mett H; Bergeron RJ; Porter CW
Cancer Res; 1998 Sep; 58(17):3883-90. PubMed ID: 9731498
[TBL] [Abstract][Full Text] [Related]
18. A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors.
Hurwitz HI; Cohen RB; McGovren JP; Hirawat S; Petros WP; Natsumeda Y; Yoshinari T
Cancer Chemother Pharmacol; 2007 Jan; 59(1):139-47. PubMed ID: 16819636
[TBL] [Abstract][Full Text] [Related]
19. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
[TBL] [Abstract][Full Text] [Related]
20. Phase I and pharmacokinetic study of the polyamine synthesis inhibitor SAM486A in combination with 5-fluorouracil/leucovorin in metastatic colorectal cancer.
van Zuylen L; Bridgewater J; Sparreboom A; Eskens FA; de Bruijn P; Sklenar I; Planting AS; Choi L; Bootle D; Mueller C; Ledermann JA; Verweij J
Clin Cancer Res; 2004 Mar; 10(6):1949-55. PubMed ID: 15041711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
